Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.

Qi, Litong; Liu, Dexue; Qu, Yanling; Chen, Beijian; Meng, Haiyan; Zhu, Lei; Li, Lipeng; Wang, Shuqing; Liu, Changyi; Zheng, Guanzhong; Lian, Qiufang; Yin, Guotian; Lv, Lingchun; Lu, Di; Chen, Xiaoshu; Xue, Fengtai; An, Pei; Li, Haoyu; Deng, Huan; Li, Li; Qian, Lei; Huo, Yong

doi:10.1016/j.jacasi.2023.04.011

Public

Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.

Shared by NobleBlocks on Aug 1, 2023 • 12:00 AM UTC

Authors:

Litong Qi

Dexue Liu

Yanling Qu

Abstract

Background: Tafolecimab is a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, developed for the treatment of hypercholesterolemia. Objectives: The purpose of this study was to assess the efficacy and safety of tafolecimab in Chinese patients at high or ver...

Subject

coronary artery disease

hypercholesterolemia

low-density lipoprotein cholesterol

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!